Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DOT1L | Q8TEK3 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | ADCY5 | O95622 | 3/20 | 0.35 |
| ▸ | ENPP1 | P22413 | 2/20 | 0.35 |
| ▸ | P2RY1 | P47900 | 1/20 | 0.35 |
| ▸ | STING1 | Q86WV6 | 3/20 | 0.35 |
| ▸ | ADA | P00813 | 1/20 | 0.34 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.34 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.34 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.34 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19662810 | 0.89 | P2RX3 (0.44) | POLBP2RY1 | |
| SCHEMBL19662411 | 0.89 | P2RX3 (0.44) | POLBP2RY1 | |
| SCHEMBL21787181 | 0.86 | POLB (0.39) | DOT1LPOLBADCY5ENPP1P2RY1 | |
| SCHEMBL24913385 | 0.83 | PRKACA (0.41) | DOT1LPOLBADCY5ENPP1P2RY1 | |
| SCHEMBL21786816 | 0.80 | ADA (0.43) | DOT1LPOLBENPP1P2RY1STING1 | |
| SCHEMBL24913573 | 0.78 | — | — | |
| SCHEMBL24913388 | 0.77 | POLB (0.46) | POLB | |
| SCHEMBL19662777 | 0.77 | ADA (0.47) | DOT1LPOLBENPP1P2RY1STING1 | |
| SCHEMBL21787067 | 0.75 | P2RX3 (0.45) | POLBP2RY1 | |
| SCHEMBL21787066 | 0.75 | P2RX3 (0.45) | POLBP2RY1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230028321-A1 | NUCLEOTIDE DERIVATIVES AND METHODS OF USE THEREOF | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2023-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230028321-A1 | NUCLEOTIDE DERIVATIVES AND METHODS OF USE THEREOF | POLRMT, NSUN2, NUDT1 | DOT1L 2082/4885POLB 11/4885ADCY5 1953/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.